French Trial Tragedy: The Investigations Begin
This article was originally published in Scrip
Executive Summary
A French Senate committee has intervened in the debate over the Phase I study of a new drug that caused the death of one volunteer and left a number of others hospitalized, saying that it plans to meet with the government inspectors who visited the site in Rennes to discuss their findings, with a view to looking afresh at the legislation governing clinical trials.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.